Cannabis capsules make it simple for
patients to self-administer accurate doses
VAUGHAN, ON, April 18, 2018 /CNW/ - CannTrust Holdings Inc.
("CannTrust" or the "Company", TSX: TRST), one of Canada's leading licensed producers of
cannabis, announced that it is expanding its product offerings
to include a range of new cannabis oil vegan-based hard shell
capsules. CannTrust now offers the widest variety of cannabis
products of any licensed producer in Canada.
The Company's cannabis capsules are being launched in three
different formats: CBD 10 mg; 1:1 CBD 5 mg + THC 5 mg; and THC 10
mg. The standardized encapsulated cannabis oil is produced using
our state-of-the-art extraction technology. Each format will be
sold in a 60-capsule bottle and will be available to CannTrust
customers and physicians as of April 24,
2018.
The CannTrust cannabis oil capsules are being produced at the
Company's 50,000 square foot, state-of-the-art processing,
manufacturing and distribution facility in Vaughan, Ontario. The introduction of
the new vegan-based hard shell product line reinforces the
Company's commitment to continuous improvement, innovation,
quality, patient education and customer service.
"We are excited to be moving into this new category of the
medicinal cannabis market, one that makes it safe and easy for
patients to self-administer the correct dosage in a familiar
format. CannTrust opted for the newest encapsulation
technology so that we can use vegan-based capsules rather than an
animal by-product gelatin capsule. In addition, our capsules are
colour coded for ease of use and patient safety." said Eric Paul
CEO.
About CannTrust®
Since its inception in 2014, CannTrust has led the Canadian
market in producing pharmaceutically standardized product.
As a federally regulated licensed producer, CannTrust™ brings
more than 40 years of pharmacy and healthcare experience to the
medical cannabis industry. CannTrust currently operates a
50,000 square foot state-of-the-art hydroponic facility
in Vaughan, Ontario, as well
as the recently completed 250,000 square foot Phase 1 redevelopment
of its 430,000 square foot Niagara Greenhouse Facility. The Phase 2
expansion is underway and is anticipated to be completed and in
cultivation towards the middle of 2018.
CannTrust™ is committed to research and innovation, as well as
contributing to the growing body of evidence-based research
regarding the use and efficacy of cannabis. Our product development
teams along with our exclusive global pharma partner, Apotex Inc.,
are diligently innovating and developing products that will make it
easier for patients to use medical cannabis. We support ongoing
patient education about medical cannabis and have a compassionate
use program to support patients with financial needs.
Forward Looking Statements
This press release contains
"forward-looking information" within the meaning of applicable
Canadian securities legislation, which are based upon CannTrust's
current internal expectations, estimates, projections, assumptions
and beliefs and views of future events. Forward-looking information
can be identified by the use of forward-looking terminology such as
"expect", "likely", "may", "will", "should", "intend",
"anticipate", "potential", "proposed", "estimate" and other similar
words, including negative and grammatical variations thereof, or
statements that certain events or conditions "may", "would" or
"will" happen, or by discussions of strategy.
Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, CannTrust does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for CannTrust to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in CannTrust's Final Long Form Prospectus
dated August 11, 2017 and filed with the applicable
Canadian securities regulatory authorities on SEDAR
at www.sedar.com. The risk factors and other factors noted in
CannTrust's Final Long Form Prospectus could cause actual events or
results to differ materially from those described in any
forward-looking information.
SOURCE CannTrust Holdings Inc.